The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma.
DNA damage
drug resistance
genomic instability
mouse models
multiple myeloma
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
03
2019
accepted:
15
07
2019
entrez:
3
9
2019
pubmed:
3
9
2019
medline:
3
9
2019
Statut:
epublish
Résumé
Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation of clonal plasma cells in the bone marrow. In normal plasma cell development, cells undergo programmed DNA breaks and translocations, a process necessary for generation of a wide repertoire of antigen-specific antibodies. This process also makes them vulnerable for the acquisition of chromosomal defects. Well-known examples of these aberrations, already seen at time of MM diagnosis, are hyperdiploidy or the translocations involving the immunoglobulin heavy chain. Over the recent years, however, novel aspects concerning genomic instability and its role in tumor development, disease progression and nascence of refractory disease were identified. As such, genomic instability is becoming a very relevant research topic with the potential identification of novel disease pathways. In this review, we aim to describe recent studies involving murine MM models focusing on the deregulation of processes implicated in genomic instability and their clinical impact. More specifically, we will discuss chromosomal instability, DNA damage and repair responses, development of drug resistance, and recent insights into the study of clonal hierarchy using different murine MM models. Lastly, we will discuss the importance and the use of murine MM models in the pre-clinical evaluation of promising novel therapeutic agents.
Identifiants
pubmed: 31475039
doi: 10.3389/fgene.2019.00740
pmc: PMC6704229
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
740Références
Acta Oncol. 2000;39(7):771-6
pubmed: 11145431
N Engl J Med. 2002 Feb 21;346(8):564-9
pubmed: 11856795
Immunol Rev. 2003 Aug;194:196-206
pubmed: 12846816
Nature. 1962 Mar 17;193:1086-7
pubmed: 14488296
Br J Cancer. 1992 Dec;66(6):1088-93
pubmed: 1457349
Cancer Res. 2003 Oct 15;63(20):6689-96
pubmed: 14583463
J Cell Sci. 2004 Jun 15;117(Pt 14):3061-71
pubmed: 15173319
J Clin Invest. 2004 Jun;113(12):1763-73
pubmed: 15199411
Leukemia. 2004 Nov;18(11):1891-7
pubmed: 15385929
Radiat Res. 2004 Aug;162(2):128-35
pubmed: 15387139
EMBO J. 2004 Dec 8;23(24):4868-75
pubmed: 15549137
Blood. 2005 Jul 15;106(2):713-6
pubmed: 15817674
Nat Genet. 2006 Sep;38(9):1043-8
pubmed: 16921376
Blood. 2007 Mar 1;109(5):2106-11
pubmed: 17068150
Blood. 2007 Mar 15;109(6):2276-84
pubmed: 17105813
Cancer Cell. 2007 Apr;11(4):349-60
pubmed: 17418411
Cancer Cell. 2008 Feb;13(2):167-80
pubmed: 18242516
Am J Hematol. 2009 Jan;84(1):6-14
pubmed: 18980173
Blood. 2009 Mar 5;113(10):2290-7
pubmed: 19050310
Cancer Res. 2009 Sep 1;69(17):6899-905
pubmed: 19690141
Mol Cell. 2010 Oct 22;40(2):179-204
pubmed: 20965415
Haematologica. 2011 Apr;96(4):574-82
pubmed: 21173094
Cancer Res. 2011 Jan 15;71(2):339-48
pubmed: 21224354
Leukemia. 2011 Apr;25(4):707-11
pubmed: 21233838
Leukemia. 2011 Aug;25(8):1344-53
pubmed: 21566653
Cell Cycle. 2011 Oct 1;10(19):3269-73
pubmed: 21941087
Blood. 2012 Jul 12;120(2):376-85
pubmed: 22451422
Blood. 2012 Aug 2;120(5):1067-76
pubmed: 22498740
BMC Cell Biol. 2012 Jun 19;13:15
pubmed: 22712476
Genome Integr. 2012 Nov 27;3(1):9
pubmed: 23181949
PLoS One. 2012;7(12):e51892
pubmed: 23284805
Cancer Cell. 2013 Jan 14;23(1):48-62
pubmed: 23328480
Clin Cancer Res. 2013 Jun 1;19(11):3019-31
pubmed: 23584492
Cell Rep. 2013 May 30;3(5):1389-97
pubmed: 23643536
Ann Oncol. 2013 Oct;24 Suppl 6:vi133-7
pubmed: 23956208
Cell Cycle. 2013 Sep 1;12(17):2760-73
pubmed: 23966156
Cell Death Dis. 2013 Sep 12;4:e798
pubmed: 24030150
J Cancer. 2013 Sep 10;4(8):614-25
pubmed: 24155773
Nat Commun. 2014;5:2997
pubmed: 24429703
Cancer Cell. 2014 Jan 13;25(1):91-101
pubmed: 24434212
Leukemia. 2014 Aug;28(8):1705-15
pubmed: 24480973
Nat Biotechnol. 2014 Apr;32(4):364-72
pubmed: 24633240
Oncotarget. 2014 May 30;5(10):3115-29
pubmed: 24833108
Leukemia. 2014 Dec;28(12):2410-3
pubmed: 25079174
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Clin Cancer Res. 2015 May 15;21(10):2399-411
pubmed: 25724519
PLoS One. 2015 Mar 19;10(3):e0121581
pubmed: 25790254
Blood. 2015 May 14;125(20):3049-58
pubmed: 25838343
Bone. 2015 Aug;77:57-68
pubmed: 25868800
Elife. 2015 Apr 28;4:null
pubmed: 25918846
Cancer Discov. 2015 Sep;5(9):972-87
pubmed: 26080835
J Clin Oncol. 2015 Nov 20;33(33):3911-20
pubmed: 26282654
Leukemia. 2016 Apr;30(4):873-82
pubmed: 26648534
Mol Cancer Ther. 2016 Feb;15(2):241-50
pubmed: 26719576
Leukemia. 2016 Nov;30(11):2187-2197
pubmed: 27118403
Blood. 2016 Sep 29;128(13):1735-44
pubmed: 27516441
Nat Rev Clin Oncol. 2017 Feb;14(2):100-113
pubmed: 27531699
J Hematol Oncol. 2016 Aug 24;9(1):73
pubmed: 27557643
Nat Med. 2016 Nov;22(11):1351-1357
pubmed: 27723723
Oncotarget. 2016 Nov 29;7(48):78896-78909
pubmed: 27806331
Leukemia. 2017 May;31(5):1123-1135
pubmed: 27857131
Leuk Lymphoma. 2017 Aug;58(8):1823-1831
pubmed: 28078910
Clin Epigenetics. 2017 Jan 19;9:4
pubmed: 28149332
Oncotarget. 2017 Apr 18;8(16):26718-26731
pubmed: 28157697
Expert Opin Investig Drugs. 2017 Jun;26(6):699-711
pubmed: 28448171
J Hematol Oncol. 2017 Jun 20;10(1):127
pubmed: 28633670
Br J Haematol. 2017 Oct;179(1):66-74
pubmed: 28653400
Blood. 2017 Sep 28;130(13):1514-1522
pubmed: 28774880
Nat Commun. 2017 Aug 16;8(1):268
pubmed: 28814763
Neoplasia. 2017 Dec;19(12):972-981
pubmed: 29091798
J Clin Oncol. 2018 Mar 20;36(9):859-866
pubmed: 29381435
Blood Cancer J. 2018 Feb 15;8(2):22
pubmed: 29449574
Leukemia. 2018 Dec;32(12):2636-2647
pubmed: 29895955
J Exp Clin Cancer Res. 2018 Aug 29;37(1):205
pubmed: 30157958
Blood Cancer J. 2018 Sep 25;8(10):92
pubmed: 30301882
Sci Rep. 2018 Oct 9;8(1):15030
pubmed: 30301958
Blood. 2018 Dec 13;132(24):2546-2554
pubmed: 30352784
BMC Cancer. 2018 Nov 21;18(1):1152
pubmed: 30463534
J Hematol Oncol. 2018 Dec 13;11(1):137
pubmed: 30545397
J Hematol Oncol. 2018 Dec 20;11(1):141
pubmed: 30572922
Medicine (Baltimore). 2019 Jan;98(3):e14069
pubmed: 30653121
Mol Ther Oncolytics. 2018 Dec 06;12:93-102
pubmed: 30719499
Theranostics. 2019 Jan 1;9(2):540-553
pubmed: 30809292
Am J Pathol. 1988 Sep;132(3):593-7
pubmed: 3414786
J Immunol. 1979 Feb;122(2):609-13
pubmed: 368243
Nature. 1969 Jun 7;222(5197):994-5
pubmed: 5789334
Bone. 1997 Jun;20(6):515-20
pubmed: 9177864
Blood. 1997 Jul 15;90(2):754-65
pubmed: 9226176
Blood. 1998 Oct 15;92(8):2908-13
pubmed: 9763577